A deadly organometallic luminescent probe: anticancer activity of a ReI bisquinoline complex.

The photophysical properties of [Re(CO)3 (L-N3)]Br (L-N3 =2-azido-N,N-bis[(quinolin-2-yl)methyl]ethanamine), which could not be localized in cancer cells by fluorescence microscopy, have been revisited in order to evaluate its use as a luminescent probe in a biological environment. The Re(I) complex displays concentration-dependent residual fluorescence besides the expected phosphorescence, and the nature of the emitting excited states have been evaluated by DFT and time-dependent (TD) DFT methods. The results show that fluorescence occurs from a (1) LC/MLCT state, whereas phosphorescence mainly stems from a (3) LC state, in contrast to previous assignments. We found that our luminescent probe, [Re(CO)3 (L-N3)]Br, exhibits an interesting cytotoxic activity in the low micromolar range in various cancer cell lines. Several biochemical assays were performed to unveil the cytotoxic mechanism of the organometallic Re(I) bisquinoline complex. [Re(CO)3 (L-N3)]Br was found to be stable in human plasma indicating that [Re(CO)3 (L-N3)]Br itself and not a decomposition product is responsible for the observed cytotoxicity. Addition of [Re(CO)3 (L-N3)]Br to MCF-7 breast cancer cells grown on a biosensor chip micro-bioreactor immediately led to reduced cellular respiration and increased glycolysis, indicating a large shift in cellular metabolism and inhibition of mitochondrial activity. Further analysis of respiration of isolated mitochondria clearly showed that mitochondrial respiratory activity was a direct target of [Re(CO)3 (L-N3)]Br and involved two modes of action, namely increased respiration at lower concentrations, potentially through increased proton transport through the inner mitochondrial membrane, and efficient blocking of respiration at higher concentrations. Thus, we believe that the direct targeting of mitochondria in cells by [Re(CO)3 (L-N3)]Br is responsible for the anticancer activity.

[1]  M. Herlyn,et al.  Rhenium Complexes with Visible‐Light‐Induced Anticancer Activity , 2013, ChemMedChem.

[2]  Nicolas P E Barry,et al.  Exploration of the medical periodic table: towards new targets. , 2013, Chemical communications.

[3]  J. Platts,et al.  Emission wavelength variation with changes in excitation in a Re(I)–bisthiazole ligand complex that breaks the Kasha–Vavilov rule , 2013 .

[4]  J. Keiser,et al.  [(η(6)-Praziquantel)Cr(CO)3] derivatives with remarkable in vitro anti-schistosomal activity. , 2013, Chemistry.

[5]  Y. Yan,et al.  Rhenium(I) tricarbonyl complexes of salicylaldehyde semicarbazones: synthesis, crystal structures and cytotoxicity. , 2013, Journal of inorganic biochemistry.

[6]  L. Spiccia,et al.  Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid. , 2012, Journal of the American Chemical Society.

[7]  J. Keiser,et al.  Ferrocenyl derivatives of the anthelmintic praziquantel: design, synthesis, and biological evaluation. , 2012, Journal of medicinal chemistry.

[8]  C. Crespo-Hernández,et al.  Subpicosecond intersystem crossing in mono- and di(organophosphine)gold(I) naphthalene derivatives in solution. , 2012, Journal of the American Chemical Society.

[9]  J. Sýkora,et al.  Spin-orbit treatment of UV-vis absorption spectra and photophysics of rhenium(I) carbonyl-bipyridine complexes: MS-CASPT2 and TD-DFT analysis. , 2012, The journal of physical chemistry. A.

[10]  P. Dyson,et al.  Challenges and Opportunities in the Development of Organometallic Anticancer Drugs , 2012 .

[11]  G. Morgant,et al.  Combination of three metals for the treatment of cancer: gallium, rhenium and platinum. 1. Determination of the optimal schedule of treatment. , 2012, Anticancer research.

[12]  G. Gasser,et al.  Small organometallic compounds as antibacterial agents. , 2012, Dalton transactions.

[13]  S. Wölfl,et al.  A spontaneous gold(I)-azide alkyne cycloaddition reaction yields gold-peptide bioconjugates which overcome cisplatin resistance in a p53-mutant cancer cell line , 2012 .

[14]  C. Supuran,et al.  [(Cp-R)M(CO)3] (M=Re or 99mTc) Arylsulfonamide, arylsulfamide, and arylsulfamate conjugates for selective targeting of human carbonic anhydrase IX. , 2012, Angewandte Chemie.

[15]  Gilles Gasser,et al.  The potential of organometallic complexes in medicinal chemistry. , 2012, Current opinion in chemical biology.

[16]  S. Wölfl,et al.  Cellular impact and selectivity of half-sandwich organorhodium(III) anticancer complexes and their organoiridium(III) and trichloridorhodium(III) counterparts , 2012, JBIC Journal of Biological Inorganic Chemistry.

[17]  R. Heumann,et al.  Synthesis, characterisation and bioimaging of a fluorescent rhenium-containing PNA bioconjugate. , 2012, Dalton transactions.

[18]  R. Heumann,et al.  Preparation and Biological Evaluation of Di-Hetero-Organometallic-Containing PNA Bioconjugates , 2011 .

[19]  S. Wölfl,et al.  Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type. , 2011, Journal of medicinal chemistry.

[20]  Andreas F. Rausch,et al.  The triplet state of organo-transition metal compounds. Triplet harvesting and singlet harvesting for efficient OLEDs , 2011 .

[21]  P. Chou,et al.  Harvesting luminescence via harnessing the photophysical properties of transition metal complexes , 2011 .

[22]  Gregory S. Smith,et al.  Targeted and multifunctional arene ruthenium chemotherapeutics. , 2011, Dalton transactions.

[23]  J. Zubieta,et al.  Synthesis, cytotoxicity and cellular uptake studies of N3 functionalized Re(CO)3 thymidine complexes. , 2011, Dalton transactions.

[24]  Stefan Wölfl,et al.  Real-Time Monitoring of Cisplatin-Induced Cell Death , 2011, PloS one.

[25]  M. Chergui,et al.  Relativistic effects in spectroscopy and photophysics of heavy-metal complexes illustrated by spin–orbit calculations of [Re(imidazole)(CO)3(phen)]+ , 2011 .

[26]  I. Clark,et al.  Ultrafast excited-state dynamics of rhenium(I) photosensitizers [Re(Cl)(CO)3(N,N)] and [Re(imidazole)(CO)3(N,N)]+: diimine effects. , 2011, Inorganic chemistry.

[27]  P. Roussel,et al.  Synthesis, structural characterization and biological activity against several human tumor cell lines of four rhenium(I) diseleno-ethers complexes: Re(CO)3Cl(PhSe(CH2)2SePh), Re(CO)3Cl(PhSe(CH2)3SePh), Re(CO)3Cl(HO2C–CH2Se(CH2)2SeCH2–CO2H) and Re(CO)3Cl(HO2C–CH2Se(CH2)3SeCH2–CO2H) , 2011 .

[28]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[29]  S. Wölfl,et al.  Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. , 2010, Journal of medicinal chemistry.

[30]  J. Steinbach,et al.  Preparation, 99mTc-labeling and biodistribution studies of a PNA oligomer containing a new ligand derivative of 2,2'-dipicolylamine. , 2010, Journal of inorganic biochemistry.

[31]  J. Zubieta,et al.  Synthesis, Cytotoxicity, and Insight into the Mode of Action of Re(CO)3 Thymidine Complexes , 2010, ChemMedChem.

[32]  C. Biot,et al.  Bioorganometallic Chemistry and Malaria , 2010, Medicinal Organometallic Chemistry.

[33]  P. Moreau,et al.  Synthesis and in vitro antiproliferative activities of quinoline derivatives. , 2010, European journal of medicinal chemistry.

[34]  G. Süss-Fink Arene ruthenium complexes as anticancer agents. , 2010, Dalton transactions.

[35]  P. Sadler,et al.  Activation Mechanisms for Organometallic Anticancer Complexes , 2010 .

[36]  K. K. Lo,et al.  Luminescent Polypyridinerhenium(I) Bis‐Biotin Complexes as Crosslinkers for Avidin , 2009 .

[37]  H. Gray,et al.  Relaxation dynamics of Pseudomonas aeruginosa Re(I)(CO)3(alpha-diimine)(HisX)+ (X = 83, 107, 109, 124, 126)Cu(II) azurins. , 2009, Journal of the American Chemical Society.

[38]  P. Niehoff,et al.  Synthesis, structural characterisation and anti-proliferative activity of NHC gold amino acid and peptide conjugates. , 2009, Dalton transactions.

[39]  J. Zubieta,et al.  Targeting the cubilin receptor through the vitamin B(12) uptake pathway: cytotoxicity and mechanistic insight through fluorescent Re(I) delivery. , 2009, Journal of medicinal chemistry.

[40]  K. K. Lo,et al.  Novel Luminescent Tricarbonylrhenium(I) Polypyridine Tyramine-Derived Dipicolylamine Complexes as Sensors for Zinc(II) and Cadmium(II) Ions , 2009 .

[41]  M. Towrie,et al.  Excited-state relaxation dynamics of Re(I) tricarbonyl complexes with macrocyclic phenanthroline ligands studied by time-resolved IR spectroscopy. , 2009, Dalton transactions.

[42]  Christian G Hartinger,et al.  Bioorganometallic chemistry--from teaching paradigms to medicinal applications. , 2009, Chemical Society reviews.

[43]  A. Wedel,et al.  Photophysical properties of Re(pbt)(CO)4 studied by high resolution spectroscopy , 2009 .

[44]  J. Zubieta,et al.  Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals. , 2009, Chemical communications.

[45]  Anna F. A. Peacock,et al.  Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. , 2008, Chemistry, an Asian journal.

[46]  J. Zubieta,et al.  Targeting the Folate Receptor (FR): Imaging and Cytotoxicity of ReI Conjugates in FR‐Overexpressing Cancer Cells , 2008, ChemMedChem.

[47]  D. Ho,et al.  The one-pot synthesis and the fluorescence and cytotoxicity studies of chlorotricarbonyl(α-diimine)rhenium(I), fac -(CO) 3 (α-diimine)ReCl, complexes , 2008 .

[48]  Ingo Ott,et al.  Cellular Uptake, Cytotoxicity, and Metabolic Profiling of Human Cancer Cells Treated with Ruthenium(II) Polypyridyl Complexes [Ru(bpy)2(NN)]Cl2 with NN=bpy, phen, dpq, dppz, and dppn , 2008, ChemMedChem.

[49]  M. Chergui,et al.  Femtosecond fluorescence and intersystem crossing in rhenium(I) carbonyl-bipyridine complexes. , 2008, Journal of the American Chemical Society.

[50]  P. Sadler,et al.  New trends for metal complexes with anticancer activity. , 2008, Current opinion in chemical biology.

[51]  J. Sýkora,et al.  Solvation-driven excited-state dynamics of [Re(4-Et-Pyridine)(CO)3(2,2'-bipyridine)]+ in imidazolium ionic liquids. A time-resolved infrared and phosphorescence study. , 2008, The journal of physical chemistry. A.

[52]  K. K. Lo,et al.  Rhenium(I) polypyridine biotin isothiocyanate complexes as the first luminescent biotinylation reagents: synthesis, photophysical properties, biological labeling, cytotoxicity, and imaging studies. , 2008, Inorganic chemistry.

[53]  G. Sheldrick A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[54]  Dik‐Lung Ma,et al.  DNA binding and cytotoxicity of ruthenium(II) and rhenium(I) complexes of 2-amino-4-phenylamino-6-(2-pyridyl)-1,3,5-triazine. , 2007, Inorganic chemistry.

[55]  B. P. Sullivan,et al.  Photochemistry and Photophysics of Coordination Compounds: Rhenium , 2007 .

[56]  P. Sadler,et al.  Ruthenium Arene Anticancer Complexes , 2006 .

[57]  J. Zubieta,et al.  Developing the {M(CO)3}+ core for fluorescence applications: Rhenium tricarbonyl core complexes with benzimidazole, quinoline, and tryptophan derivatives. , 2006, Inorganic chemistry.

[58]  Laurent Porrès,et al.  Absolute Measurements of Photoluminescence Quantum Yields of Solutions Using an Integrating Sphere , 2006, Journal of Fluorescence.

[59]  Helmut Schönenberger,et al.  Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity , 2005, Journal of Cancer Research and Clinical Oncology.

[60]  J. Brennan,et al.  Bridging the gap between in vitro and in vivo imaging: isostructural Re and 99mTc complexes for correlating fluorescence and radioimaging studies. , 2004, Journal of the American Chemical Society.

[61]  J. Zubieta,et al.  A new strategy for the preparation of peptide-targeted radiopharmaceuticals based on an fmoc-lysine-derived single amino acid chelate (SAAC). automated solid-phase synthesis, NMR characterization, and in vitro screening of fMLF(SAAC)G and fMLF[(SAAC-Re(CO)3)+]G. , 2004, Bioconjugate chemistry.

[62]  Hartmut Yersin,et al.  Triplet emitters for OLED applications. Mechanisms of exciton trapping and control of emission properties , 2004 .

[63]  C. Orvig,et al.  Boon and Bane of Metal Ions in Medicine , 2003, Science.

[64]  J. Vittal,et al.  Synthesis, X-ray structures, and cytotoxicity of rhenium(I) carbonyl 2-(dimethylamino)ethoxide complexes , 2002 .

[65]  J. Vittal,et al.  Tricarbonylrhenium(I) complexes of phosphine-derivatized amines, amino acids and a model peptide: structures, solution behavior and cytotoxicity , 2002 .

[66]  B Wolf,et al.  Multiparametric microsensor chips for screening applications , 2001, Fresenius' journal of analytical chemistry.

[67]  I. Wilson,et al.  Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. , 2000, European journal of biochemistry.

[68]  Maria Cristina Burla,et al.  SIR97: a new tool for crystal structure determination and refinement , 1999 .

[69]  Vincenzo Barone,et al.  Exchange functionals with improved long-range behavior and adiabatic connection methods without adjustable parameters: The mPW and mPW1PW models , 1998 .

[70]  Wang,et al.  Generalized gradient approximation for the exchange-correlation hole of a many-electron system. , 1996, Physical review. B, Condensed matter.

[71]  Burke,et al.  Generalized Gradient Approximation Made Simple. , 1996, Physical review letters.

[72]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[73]  G. Kroemer,et al.  Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death , 1995, The Journal of experimental medicine.

[74]  W. R. Wadt,et al.  Ab initio effective core potentials for molecular calculations , 1984 .